Skip to main content

Table 1 Summary of Kaplan–Meier survival analysis of the E0771 in-vivo study (Fig. 3)

From: Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

 

Median survival

 

Control (c44)

mch1N11

aPD-1

mch1N11 + aPD-1

Days

25

32

55

Undefined

Hazard ratio

0.1915

0.089

0.04557

CI of HR at 95 %

0.003086–0.03911

0.0001420–0.004134

3.222 × 10–5–0.001361

Mice with complete regression

0

0

2

6

  1. Data include median survival (days), hazard ratio (HR) confidence interval (CI) at 95 % of HR, and number of animals with each treatment that experienced complete tumor regression